• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immix Biopharma, Inc. - Common Stock (NQ: IMMX )

    2.360 +0.400 (+20.41%)
    Streaming Delayed Price Updated: 11:46 AM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 565,310
    Open 2.030
    Bid (Size) 2.360 (14)
    Ask (Size) 2.380 (10)
    Prev. Close 1.960
    Today's Range 2.020 - 2.480
    52wk Range 1.550 - 7.750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
    IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -61.05%
    -61.05%
    1 Month
    +21.03%
    +21.03%
    3 Month
    -19.72%
    -19.72%
    6 Month
    -61.05%
    -61.05%
    1 Year
    -20.80%
    -20.80%

    More News

    Read More
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma on Track to Dose NXC-201 Patients in United States
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
    Via InvestorPlace
    Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
    Via Investor Brand Network
    Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Proposed Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.